Pre-treatment effects of continuous and intermittent endurance training on gene expression of myocardial Osteopontin in male Wistar rats following the induction of myocardial infarction

(1)

/

1

98

: *

! "#$ $ %"#$ "# &

'() :* # + $ vahidtadibi@razi.ac.ir

! "

#$% & **' ( ) *% + ,**

1 2

*

! "# 2 3

4

1 - !

" #

2 -

" # %

3 -

#

' " ( ) % * % * + , ,-.

" /0

4 -

# 2 3 4 " ( 2 / 5 6 7 + , ,-.

' " ( )

" /0

! / #

$ # %&'(

! /

2 /

&( * 98

-& & / 80

: 17 / 1 / 98 :

11 / 3 / 98

:'

( ))* +" , - . - )/ ' 01 2 3 4#

5 6 7 / 8 5 9

! 6 . 6)*

6 )

6 ; ;6< ! 6 ( . - = , >? < @ 9 A =9 B, . );C9 ; ;< D ) * , 9 E 1 F

D GHI 2# ! ; , J;< -K - - E ) 2# 8 D ( L M ;* N ? ;C 9

.

0 : 9

A =9 B, 2

32 ( 68 O3 6< 9 6L ( 8) ( 8 Q ' + ;< R L 2 D <

6L 9

6, F6C 9 6L ( 8 M ;* N ? 3 - O3 < 9 L ( 8 . L O C ( ) ! ( 8 ! ( 8 FC 1 T

( 8 . L U; HI M ;* N ? ' ';N9 2"9 9

;V , 7 ; ;< D ) ' ';N9 2"9 D ' E ) T6, )

1 48 L U; HI M ;* N ? ' 2 ;< 2/ <

D GHI FC X 1 - ) Y 3 1 T, ';N9 . . 26 Z 6Z 69

(1 6 -

-K - 8 0 1 HIOPN

qRT-PCR . 8 ( N;<

';#

9 : ';#

-K - - " A =9 B, 9 D GHI 2# OPN

'6 2 6C 6 HI M ;* N ? 3 1 T, ;C 9 ( 68

) * , )4 = E# O3 < 9 L 05

/ 0 p<

^ 6 6)4 6Y ' FC 9 L ( 8 *_ -K C - ! )` 9 .(

69 1

( 8

) 9

) 05 / 0 p<

-K - C - E ! a 'C .(

) ; * ( 8 OPN 05

/ 0 p<

.(

'X ; b 8

: GHI 1 # I / HI 1 cV 9 ;* # = E# b/ M ;* N ? ' U;

;6< D 6) . 68 '6 ;

O ) ! (B

# ! = E#

. )* 7 4 9 ;*

(K

: H* 9

; ;< ! - = , HI M ;* N ? ! ; , J;<

(2)

# 9 ) : ( " " / / / ;. # . # , ( 9 2. " # < ) =0 .

...

,# 2-#

" 2*

'

; / ; > 6 ? @ 7 ( A ) / 2* B # ' A 4 C A( 6 7 A DE F.

# 2 / A ) 9 3 GHI / J /

< ) . -

; /

# " * K ( . C *

2020 9 I #

2 / * 25 N# C/ A ;* ' / 7 " #

) ;* ' N @. . # P # > 2 1

.(

) ( R ' S . # + F. T

# (ECM -

) @ 7 @ C/ !;# . 2

S . # @ .(

# U ( R '

2 # / D

# + F. 9 C 2V . @ 7 " I < C/ " .

W 9X/ Y( < 6@( 4V . N/ 7 T C/ C I @ Z . KI ' ! ;X/ % ) N D. [\

6 7 K , <* J / A 4 C " I

# 6 7 U @, KI ' )

3 .(

( " ]# " I A / . U 2 0 6 7 ) *

# ) ) / 4 . A( ; ^% .(

( R ' S . # @ / + D X# " ; ] T ;F# @] ) 2V 4. ? B _ T /

A( C % + ` (6 7 )

5 .(

. N C/

C `

A D2V C2* / @ 7 / a.

+I # *

/ ? b;# C/ * # / ^ ( @ 7

# 2 / c Y .

) / ^# .

6 9 .(

F. ;* c Y . A 4( C/ !;# A 4 " # / C! [\ 9X/ A#I " / 2

e (

# . . . K ; 4/ 2 / A ) "

" 2 / ( ; 24# <, * # / A, ,3

# ^ @ 7 ( U D#

C/ V 9 / . ;;

2 / / c Y . / . V * # /

S D;# C V

G] # ;;

*

) A4V + ^ # . )

/ ? A

" # 9 ;f2*

) ; / ` a ' * 7

.(

9 ) : ( 9 ( C

Eta-1 - . 9 :. ) ^]

1 ) (SPP1

# # W C A( 9 :. ) % >

K ( h Y#

A ( # A(I/ @ C 2V * 6 7 *

# " / )

8 ( j > 9 ) : ( . 297

#0 ( C;

-

3 # "

33 '

9 :. ) " ; C/ C A( ( R ' S . # *

3 K -# 9 ( >

9 ;\ C/ Na # RGD

N# D.

;;

9 ; C 2V 9 ; ᵦ1

l . 2 C

# " / # ) V

9 3 + % .(

9 9 ; / 9 ) : ( C A(

m C/ h Y# *

C ( 9 ; ɑv

) ᵝ1

ɑv

، ᵝ5

ɑv

، ᵝ3

ɑv

/ (

# /

) 10 ( 3 + , ,-. K 3 9 / . K a.

/ OPN

) ᵝ1

ɑ9

( ) ᵝ1

ɑ8

) ( ᵝ1

ɑ4

(

# / ) 11 12 ( / I .

K ( % ZX( C/ 9 ) : ( K a. + D X# 9 ; ? ;

" CD44 )

13 T C/ (

) )0 ; 0 % 9 2* _ T 9 ) : ( C C @ n ( ; # P # ]# A '

# < > 2(I) 0 ) *

14 cY # 9 ;f2* .(

V C A(

@ <* / CD44

B #

2 ] *

) A( o@. # 15

9 / I .(

" I @ <* lp 2D#

B # I 7 * OPN

) A( * #

16 * ]# > . 2 2 .(

> -. ; ( "0 K @ C/ 6 7 o( . OPN

) )0 ) N

1 ( ) A( CH 13

.(

# " + D X# 9 ;f2*

9 ) : q( Cq ;*

( 9 Cq ' # A q ) ?0 ( ( G4# *

) Aq( @ ; 0 ;;

17 " q 2* S q/ .(

) 2018

< ) @ 7 * 9 / C " (

; /

" Iqq ;qq( * qq " qqf2* qq;;

TGF1-ᵦ

CTGF MMPs TIMP-1

9 ) : q( 4;. OPN

q/

@ 7 * # ) U A( o@. # 7

.

(3)

# 9 ) : ( " " / / / ;. # . # , ( 9 2. " # < ) =0 ....

,# 2-#

2*

"

/

3

98

7FL 1 - D e;f - "

( )9 9 C g) 3 )+ <

1 ;, ,?

2 <

HI . ( L R<

) ! ; , J;<

13 (

9 :. q) >q 9 ) : q( q4;. Cq 9q q/ I

q( R ' S . # @ ; 0 K ; -#

; 0 G4# # / > C / A(

< ) c Y . -

qq# qq; / ) qq /

18 " qq 2* rp + qqD X# .(

) 2014

<q, 9 ) : q( Cq cY # ( q( (

@ 7 ( n ^ 0 . s * ( .0 ) 8 ( q,# q( .0 + D E N-# C . ` C/

qq qq Aqq OPN

) Aqq(

19 .(

K qq#

qq*

3 q < # n ( <

" q / q . q) # q@ 7 n ^ 0 " ' Cqb3I# N/ 7 A@t# G b;. 9 ) : ( )

20 .(

) " q 2* P q@ CD X#

2008 2q(I) u Xq( (

;D# T C/OPN

q@ 7 q( " 2 /

/ C] ,#

Cq! Aq < G ( * % -

C 4; ) ' %

#OPN

" q; C/ " .

< ) # / >

q( 9# # " 2 / V 4%0

^ ( @ 7 )

21 Cq B % , ,-. .(

u X(

[q\ 9qX/ q, . q] / 9 ) : ( mRNA

) Sqq CqqX/

22 qq .(

) " qq 2* A 2010

(

C " q / Cq q( Cq! 9 C/ ' *

OPN

K ( " K D vwV J / 6 7 *

#T

9q . q

"0 Cq! Cq q 9# q# Aq # Cq/ !;# ' .Aq( ]. . ) # C# A ( # 6 Y.

C ; % C! " ,,-# 9 q#OPN

Cq/ " q.

" q;

Cq/ q@ 7 q( " -# A4V # x * >

C % )

23 Cq Aq( 9q 9 q;f2* .(

OPN

/ 5 ;2. 7 2 ] K a. y ' q# 5 q " q C^ q] A 3 J / C#

q%

) 24 .(

Aqq4V / qq ) qq* / qq # , qq( + qq; 2.

" # % V ) A( @ 7 (

25 q' / z .(

A( 9 2# A D C A( "0 3 + D X#

. q / C q "0 A#Iq( 6q 7 2 / . ^ # =0 ) " q 2* n q C 2 / 2004

q " q; (

qT Cq/ # , q( + q; 2. C/ A@] # ,# + ; 2.

q# < @ 7 2 ] 2 \ q*

) 26 .(

q

9 G?

3 <* 3 * 30

. 35

`

C/ I / X' A( A ];V N, ]# K D CAD

) 27 9 q / q/ Aq D q7 K 2 3 C/ 9 / ;/ .(

) = . =0 C; # 9 2* . CAD

C/ A@] / A D < A@t#

q/ r q-. q/

) " 2* s( 6 7 2016

ZXq( { @. ( / C/ (

" q,,-# 9q . ; ' ) 6 7 9 ) : ( / / A D q/ qX' qT Cq/ ( 9 ) : ( ,# C ;

" 2 / / A D ZX(

Sq CqX/ CAD

C q

) : ( ,# / < / A D ZX( C\ * 9

# ;D# <*

ZXq( q C ^% CD X# 9 . /

Aq( 9q 2# q/ K qD " q2 / 9 ) : ( 9 ) C Aq D v q4 <* q q m 0 < q

J / W E # 9 9 / ;/ / " C^ ] Gq4

q@ 7 " q2 / q/ Aq D j# =0 (

% 7 ) 28 .(

q# Cq/ q. 9q q/ Iq q/

9 ) : q( " " / / h Y# + ; 2. =0 C] ,#

Cq/

(4)

# 9 ) : ( " " / / / ;. # . # , ( 9 2. " # < ) =0 ....

,# 2-#

" 2*

" # 2* T CD X#

9 q;f2* .Aq( Cq + q`

xI' / 9 ) : q( q= q/ q;@# B q% 9 q;\

) )0 ; 0 q2 + IT +I' #

C ' # C; # q/ B q/ A D =0

wq# "

q A D " # < ) =0 9 / I . V 9 ) : ( " " / / C 2

* n ^ 0 \ C

# @ 7 " 9q " q / 0 C ; .A( ( /

# 0 (9 ) : ( ) q C,/ q( " q/ / *

\ S) + q^ # Gq* q/ q@ 7 n q^ 0 Cq/ "

q=0 q( / Cq/ C G "0 / # 9 |C A]*

9 q2. p / + / / ;. 9 2. > " # < ) q # 9 ) : ( " " / / o( # + / # . + qq@ 7 n q^ 0 q, Sq) qq] q q*

.G s/

0 9

q% < q# 0 % / !. <* m) 9 qE 3 _ ,-. .A % ! a. e . / * 38

] m -` + ( 8

- 6 C ^*

" / 250 -

200 + . v Y # % " q4. ( ) ] *

# N . ) ?0 N@7 C ^* > ' ' * m) + , ,-.

q C/ C ]/ ) /0

" % q V q( # 0 (" ( " ( ) C' \ / 7 . 12

) q# . ; C ( 3

22± ( CV ) v X# A/ T ( %

24-22 ( `

n q( / . q 4 w? v0 C/ C 0 ( ( / ^ q( A@7 # b;# C/ # _ ,-. 2;*

Cq % q* Cq q/ 9q / BI. * # 0 + 3 Cq@;V . q% xwq3 + 3 E ? n ( q*

Aq@7 # q2;* q/ _q@X;# + q 3 q/ q 7I' A#Iq( q # Cq]( #) * q # 0 + 3 ^ (

#0 - # +p /

2011 / ( ) 29 q# 9 (

q ) q q q ) 5I' C 2 6 a. C/

q + q 3 q/ q 5Iq' Cq 2 " ( 2 /) # 01

- 2 - 397 + . ( ( q% *

*) ; 2.

10 ) * q % ( ( 8

" q/ q(

n ^ 0 , 10

/ ( G q],. (n q^ 0 q,

+ A 4 . q( * q q% q*

Cq 3 # q( >q * / ;. # . 9 2. % % + ( > 9 ;f2* . h . n ^ 0 , . q( / " q ) Cq/ Nq . ) Aq] / q;. 9 2.

B Cq q! 0 Real time

titative q /Quan

% C 2 D.

qa. xwq3 q/ ;q / ]# *

+ ( >

"0 4 D. # . 9 2. % * q*

C/

32 % *) ( 8

K * q % .A <* ( (

6q 7 hq . Cq ^* A * S) n ^ 0 , " /

"0 q( " " / C ) ,# <!;( b;# C/ * 9 ) :

q@ 7 n q^ 0 q! Sq) C ^* > . ( / + * % C( , " ; 2T S) *

9 # q 4 / # ^ ( / )

100 mg/kg ip (

9q I ) 10 mg/kg ip (

Cq/ 7 ^q` Nq' _q .

+ q 3 6q 7 Aq / Ssq( . B 4 / _ 2 + ` A-.

# . q 0 cqaY # o( . A ( C/ N ( o

^;# # / K fY % V 70

q( CV -

. 4 %

) 7F ,

q; 2. q% p q/ + q q/ / q;. 9 2. % + q; 2. C/ C ^* A * + # C/ o( # + / # .

q q% * ; 2. ( ( . ; ' ) 6

. q/ ^` N # . Nq # . q/ ;q 0 Aq4V q /

A q( / C, 7 + # C/ z;) T " 9 2.

+ q; 2. . q; ' ) " q C/ + 3 C, 7 / # Aq * + q# q/ C qE Nq` n ( / # . / ;.

K qV) ! C ^* C] V < C ^*

1 C qE .(

2. / < _ T 6 . . C/ / ;. # . + ;

(5)

# 9 ) : ( " " / / / ;. # . # , ( 9 2. " # < ) =0 .

...

,# 2-#

2*

"

/

5

98

v ;. " # Cq] V * " ) W . % K 2 *

+ # C/ + 3 " ( % b;# C/

q/ C, 7

A ( 16 A3 q( . q; ' ) " q C/ C, 7 / #

" q # C/ / ;. % ; 2. N` 9 / K D 60

C = A ( / 16

q/ Cq, 7 q/ # )

30 q% .(

q*

q/ Nq, ;# 9 2. 5 . C/ + ; 2. " # * 9 2. " # N o -# / 9 % 7 U D# C/ .

; % 7 N # . / " " / )

31 .(

h Z 1 ) D ) 7F , .

:i 3 ( 7 ^q` Nq' _q . q/ " q 3 q /

9 # ) 100 mg/kg ip (

9 I )

10 mg/kg ip (

q/ q . "0 C; q( C]^7 C 3 Ss( . B 4 / 7 3 V AY.

" q 3 " C/ D/ .A %

) q.I q( C/

Small Animal Ventilator,

Harvard Model 683-USA qqD.) (

60 qq.

70

V G!3 C, 7 S^;.

ml/kg . q Nqa # (15

q 9 q/ qj C; ( C]^7 / / Ss(

q7 q U qD# 6 7 . ! [\ A2( 4\

> q( }q q) q# 0 C/ ) "0 S) .A % 6 / 0 [q\ q # q7 q " q q A7 /

) (LAD . @ C q` l q@ ,. "

2

# B 9q . C ]/ [\ * # 9 q]/

# 2H 2 ] 6V # } N q ) %

2 .(

Cq/ Ssq(

C p 6 . .

* q2. qD/ . q C Y/ A( ) Ij

c q' "m q] " 3 " #0 B * C/ A4V C( ) Cq/ Cq Y/ N-# 9 ( . 2) 9 ;f2* .A % 7

" ; + q 3 "0 Sq) . q q # > . / 0

^ D L ) !

j 1 91 # 91 !

1 ';N9

3 intervals, 54 m/min, 30 s

7 intervals, 54 m/min, 30 s 2 intervals, 40 m/min, 3 min

2 intervals, 40 m/min, 3 min

2 intervals, 40 m/min, 3 min 20 min, 27 m/min

22 min, 27 m/min 24 min, 27 m/min 26 min, 27 m/min 28 min, 27 m/min 30 min, 27 m/min 1

2 3 4 5 6 K C ^*

2 3 4 5 6 C ^*

2 3 4 5 6 ( C ^*

2 3 4 5 6 4\ C ^*

60 min, 27 m/min 6

- 1 C ^*

8 - 5

(6)

# 9 ) : ( " " / / / ;. # . # , ( 9 2. " # < ) =0 .

...

,# 2-#

" 2*

Cq/ 7 " ' w? v0 A % 7 S^7

" 3 N, ;# C ' Gq* .

2 q] q! q/ " q#

C " " ; 2T A4V "0 S) C ^* > 9 ;f2*

) % q + 3 "

^ q( q/ (ECG

qq 9qq qq/ . qq % Aqq@= qq V qq*

qq V % qq qq( Cqq/ * qq( ] . A@= / Na # -

" 7 /II q V *

q'0 . q ! H H I %0 * + " C ^ " ; 2T A4V CqDX7 9 q p q/ q*

* # ST n q^ 0 q/ qa' " ; C/VT

C % b # )

32 .(

7FL 2 !;# 8 I U ; ( +;< ' - h e .

9 ;F3 2 > 2 Z ;< , 1

') < 'CNI - * 1 ECG

1 1 .H < k / -? !;C LAD

' 1 < ( ? 9

> ; . " " / + F. ( / A4V E 3 CD X#

qRT-PCR R Y q( q/ qb;# 9 q/ . ^ (

;( C# RNA ) A q A cDNA

Jena

Bioscience A' ( (

q( _q@T " 2 0 Nq2D

" q / " # / b;# C/ Ss( . % ^ ( A # > "

qX,# v0 q # A^* cDNA

) # Biofact

( MasterMix Sybr Green

q2 ) q # >q q A' ( Forward

2 ) # >

Reverse q % { q Y# Gq* q/

. ) q( >q2 Cq/ ! q(

Corbett RotorGene (

) K V . #0 N2 C/ 0 2

# " * 2 ) . ( -

" qE 3 <* m) . * GAPDH

" " q; Cq/

% ^ ( S )

33 .(

h Z 2 ( L Y 9 , 3 .

? E 3 ?

C q( / ^ ` . #0 q;/

q' q*

h ` . q% " " / " # . ^ ( *

q*

B ^ q( q/ hq Y#

Ct

∆ . q % Cq] ,# ∆

>q q 0 S q Nq -. " # 0 #0 " # 0 <Y/

@q] C] ,# / . @ ,D. " # 0 C# C T

% " " / " # ZXq( . q ^ q( h Y# *

;D#

C /

" # 0

* ) 05 / 0 p<

( Cq % qb

^ ( / #0 N -. C !. . q

SPSS

CY]

22 ^ ( / * 2 G ( . Excel

CY]

2010 .A % !

';#

9

C N` 3 * <* m) 9

q,# Cq "

+ 6 7 A / 9 ) : ( " " / S) ] *

G q( * q q% Cq/ A@q] q@ 7 n ^ 0 , D# <

) ;

) A(

05 / 0 p<

( 2 ) 1 .(

Cq T >q q 0 " q# 0 ^ ( / 9 / I " q / @q] " # ;D# + ^. C "

% 9 / # @ 7 9 ) : ( "

q% 2 ] * -

; 2. * . V

S) " q# 0 ^ q( q/ "0

,D.

@ .

# Cq q cY +

q*

Cq

< q)

\

"

C/

n ^ 0

@ 7 A * C ^*

9 2.

/ q;.

# .

; A@]

/

"

w# "

C/

q;D# T

"

.

5 - 3 K a-#

9 ) : ( ) SPP1 ( F: ACAGTATCCCGATGCCACAG 139

R: ATGGCTGGTCTTCCCGTTG

S ) Gapdh ( F: CACCATCTTCCAGGAGCGA 153

R: GAAGGGGCGGAGATGATGAC

(7)

# 9 ) : ( " " / / / ;. # . # , ( 9 2. " # < ) =0 .

...

,# 2-#

2*

"

/

7

98

2 q%

K q ; 2 q]

q#

q / ) 05 / 0 p<

.(

,#

C]

2. %

;

!.

C -.

N q#0 " q

qq C

" qq #

@qq]

"

) (OPN qq) S Aqq * Cqq ^*

9 2.

# . 0 C/ " I @#

n ^

@ 7 A@]

C/

2. %

; / ;.

Cq/ " q I @# Ss(

0 n q^

@ 7

;D# <*

) 05 / 0 p<

2 ) ( 2

.(

0 2 4 6 8 10 12

OPN )∆∆−2(

*

1 -K - 2 C . )

( OPN 9 L ( 8 O3 < 9 L ( 8

FC

O3 < 9 L ( 8 )4 D N + " *

0 0.2 0.4 0.6 0.8 1 1.2

OPN)−∆∆2(

*

* **

2 ) -K - 2 C . ( 8 FC 9 L ( 8 (OPN

-

) 9

FC 9 L ( 8 )4 D N + " *

) ! ( 8 )4 D N + " **

b 'X ; 8

# / A D " # > " ; C/ B

) N#

;;

2 / / ?

*

# N2 % ? ;

) 34 n ( 9 2* / .(

" #

" # ;; ! N# e N# @ 7 (

# % >@( + F.

G4# C /

"0 9 . * K T 6( ;# / A D "

A( % )

35 .(

C/ / A D B @7 + D X# 9 / I / " ; _ D. C/ / 6( ;# C ] *

2 / A ) ' . W 9 ' @ 7 *

Y@ . # / > 9 ;f2* 7 CVD

A(

) 36 9 / 9 .(

+ ; 2.

# , (

( " # % V b;# C/ / ) * / A( @ 7 )

25 + ; 2. E 3 <* m) .(

< C ) N# > " ; C/ # , (

!. . ^ ( 7 @ 7 X' * C

" " / C " # <* m) z N -.

: ( (9 2. < ) " /) 2 ] * % 9 )

;D# T C/

< G ( * % C/ A@]

" ;\ E 3 <* m) ! A 2* # 9 2* .A

# ( / C# . <* m) 9 C % + ` *

% / 2 ] * % C] ,#

C ; 2. *

^ 0 , < ) + ; 2. C/ C ^* A * + # C/ n

" " / @] " # ; ' ) * OPN

;D# T C/ ; 2. % 9 / I . / 2

E 3 <* m) K 2 9 2. W C] ,#

+ " 9 " / @] < C cY # C *

C ^* A * + # C/ , < ) # , ( + ; 2. C/

T C/ / C ' ) # . CV . N/ 7

% 2

2.

. / / ;. 9 A( 9 3 E 3 <* m) C

# / A D W b C/ C,/ ( C .

" " / 2 < @] " # *

@ S) @ 7

@ 7 n ^ 0 C/ I / + = . # 9 / = #

n ^ 0 C/ I / < ) @ 7 A / / B A@t#

# " @ 7 E 3 _ ,-. z / ( 2* . *

) " 2* s(

2015 / A D C,/ ( =0 C/ (

5 +pI ' C/ I @# " 2 / 9 ) : ( ,# / X# . ; ' )

"0 CD u X( C " *

/ A D ZX( " # / n D# CX/ 9 ) : (

# <* m) 9 " / N p . " 2 / " .

(8)

# 9 ) : ( " " / / / ;. # . # , ( 9 2. " # < ) =0 .

...

,# 2-#

" 2*

" C^ ] v 4 <* m 0 < C/

. C,/ (

9 ^ ( /

# Kp (

# " . / A D r -.

I @# 7 @ 7 2 / C/ C I / < )

# v Y# + = ) A w% * ' V / .

28 .(

) " 2* P @ 2008

p / A 2* (

2 / N3 # @ 7 ( / { @. 9 ) : ( w # )

21 / 9 / I .(

" 2* S

) 2018 9 / C ( C! 9 C/ ' CD X# ( / 9 ) : ( 4;. @ I * # 2.

9 ;f2* .A( o@. # 7 @ 7 * # ) U C " / A( @ -# 9 :. )OPN

) 18 .(

" " / <!;( E 3 <* m) A 2* ; : (

# cY # ; C/ @ 7 A / 9 ) .

) " 2* •; ( 9 / I 2014

9 ) : ( (

9 :. ) ' 9 :. ) > " ; C/

S . # *

" / 2 " # C/ K # 6 7 C @ 7 A / (

# A-. " 9 " / " # K 3 9 / .

o

# < 6 7 . )

9 . /

o C 2 @ 7 n ^ 0 , .A( 3 *

K # N/ ,#

" 7 C 3 * OPN

€ @ 7 2 @4/ A ( # ) )0 <*

) 13 + E 3 <* m) .(

\ C *

@ 7 n ^ 0 " " /

% C/ A@] OPN

3 G ( * 9

" 2* A .A < / /

) 2010 " / C ; 4• ' + D X# (

K ( " K D vwV 6@( 6 7 9 ) : ( *

* ' 9# # A # J / ' 9 T C!

C " / ' % A( 9 2# OPN

( " -# b;# C/ # , / x * *

% @ 7 )

23 + D X# .(

, / A 2*

< ) > " ; C/OPN " 2 / ;; ; /

CDX7 " # @ 7 n ^ 0 p / 3 ST

A( (I) m 0 / )

37 .(

<* m) 3

CDX7 9 p / G* E ! CaY # " ; C/ST

+ 2 ] . ^ ( *

A D7 # N C/ 9 ;f2*

4; ) 9 ) : ( # y ' C A(

K ; ( K # 9

9 / # *

K ( ( R ' S . # A ' @ 7 *

) 38 .(

1 G ( K @#

- " * (NHE1)

>

;; G b;. "0 @ 7 m W C A( 9 :. ) % `

# 6 7 ( " PH

3 + % . /

" / < 67 D # 6 7 A DE F. <

< + D X# 9 / I .A( K @# 9 A D / 2* K @# 9 A D " / " " / <

* # 9 ) : (

<* m) 9 . V *

K @# 9 9 ) : ( 9 / # •; ; ( * ]#

. A 3 6 7 A DE F. 9 ( N# D.

,# G b;.

" " / < 6V # NHE1

S . # C ( < _ T p 2 3 9 ) : ( K D Ss( ( R ' (

CD44

9 ;

# * )

39 9 ' ( 0 b;# C/ .(

< 9 ) : ( " / < 9 / # { @. ( K @# 9 A D " / RNA-OPN

B # '

CV . 6 V . ( / @ 7 A DE F. Ss(

" B # ' / C A(

RNA-OPN N/ 7 T C/

A ( # . s * 2 \

NHE1

" B # ' 9 ;f2* . e RNA-OPN

T C/

Cb3I# N/ 7 " / A D

K ( NHE1 *

<, / . W E # 9 C <* @ 7 OPN

> . ) * }( ) }( ) .A( NHE1

> . s * C

9 ) : ( / / NHE1

# N 4].

K ; ( G b;. N, ]# % R ' *

* ; ( j3 K 3 9 / . * # € Akt

. .A( E RSK }( ) N 4]. / OPN

K @# > . s * NHE1

" ; C/ OPN

D# b;# C/ , / # x * >

+ = " n

" / C % +‚ > . s *

# NHE1 ( ;

(9)

# 9 ) : ( " " / / / ;. # . # , ( 9 2. " # < ) =0 .

...

,# 2-#

2*

"

/

9

98

) 40 9 ;f2* .(

" K D ERK 1/2

C % . *

) ; "m ] K D

# l * • (ROS -

" / < . 3 z *

# 6 7 OPN -

) / 41 ( 2 0 3 + D X# 9 V / .

+ # p T + ; 2. S) @ 7 A / @ ) A( # , ( 42

E 3 <* m) n ( 9 2* / .(

" " / A@] ;D# + ^.

% 9 / #OPN

T C/ A V / ;. # . ; 2.

A@] C

. / / ;. % 2 # . % " " / " # 9 ) : ( " " / / .p / A 7 K 2 3 C/

+ ; 2. p / + # . % C/ A@] / ;. % + 6 7 C/ 3 < / # n ( 9 *

+ ;\ * .A( / + ; 2. W

* / ;. %

C,/ ( ƒ * " / C 2 ] * % / C] ,#

" " / @] " # n ^ 0 \

;D# T C/ 9 ) : ( / 2

K 3 9 /

# . % / C] ,#

C! . / .p / " # 9

2. C " E 3 <* m) C] ,# ,#

# . + ;

# . = # T C/ @ 7 n ^ 0 C/ I / < ) -

" A@t# G b;. < ; . I / N C/OPN

C/ ! +pI ' C# @ 7 n ^ 0 C/

. ; % V "0 CX(

C ! ( C,/ ( C " E 3 <* m) *

2. C ^* A * ! Cq/ I / N@7 / + ;

+ @ 7 n ^ 0 " # <* 6@( ] *

" " qq / @qq]

"0 6qq 7 OPN

qq*

Cqq/ I qq/ Sqq)

n ^ 0 A@q] + ; 2. 9 / . * '

Cq/ Cq # q. + ; 2. p / + / / ;. + ; 2. C/

C/ C, 7 ;\ C] V * Gb;# T q 9 2. " #

#

# C ` . / q + E + ` . %

# b C/ / A D / A7 V C (

+ / ;. + ; 2.

9 ) * Cq q / + q .

. ^ ( E 3 <* m)

I F"

q! q# Cq q # 2. C ( ; / 9q

CD X#

.Gq q7 q . K q2 q

q' q * m) . q, ,-. q # 9 ;f2*

q/0

C/ C ]/

q2. Cq/ Aq4V " q( )

,. K 2 E 3 <* m) 4/ C\ * " ( .

(10)

# 9 ) : ( " " / / / ;. # . # , ( 9 2. " # < ) =0 .

...

,# 2-#

" 2*

References

1. Yuosefi P, Sabzevare S, Mohammadalizade S, Haghdoost AA. Study of quality of life in heart failure hospitalized patients in Kerman Medical University hospitals. Iran J Nurs Res. 2011; 6(21): 59 -67. (In Persian).

2. Weber KT, Pick R, Jalil JE, Janicki JS, Carroll EP. Patterns of myocardial ﬁbrosis. J Mol Cell Cardiol 1989; 21 (Suppl 5): 121 - 131.

3. Hein S, Arnon E, Kostin S, Schönburg M, Elsässer A, Polyakova V, et al.

Progression from compensated hypertrophy to failure in the pressure overloaded human heart: structural deterioration and compensatory mechanisms. Circulation.

2003; 107(7): 984 -991.

4. McLenachan JM and Dargie HJ. Ventricular arrhythmias in hypertensive left ventricular hypertrophy: relationship to coronary artery disease, left ventricular dysfunction, and myocardial ﬁbrosis. Am J Hypertens 1990;

3(10): 735 -740.

5. Nabeta T, Inomata T, Iida Y, Ikeda Y, Iwamoto M, Ishii S, et al. Baseline cardiac magnetic resonance imaging versus baseline endomyocardial biopsy for the prediction of left ventricular reverse remodeling and prognosis in response to therapy in patients with idiopathic dilated cardiomyopathy.

Heart Vessels 2014; 29(6): 784 -792.

6. Ho JE, Liu C, Lyass A, Courchesne P, Pencina MJ, Vasan RS, et al. Galectin-3, a Marker of Cardiac Fibrosis, Predicts Incident Heart Failure in the Community. JACC.

2012; 60(14): 1249 -1256.

7. Felker GM, Fiuzat M, Shaw LK, Clare R, Whellan DJ, Bettari L, et al. Galectin-3 in Ambulatory Patients with Heart Failure:

Results from the HF-ACTION Study. Circ Heart Fail. 2012; 5(1); 72 -78.

8. Wolak T. Osteopontin-a multi-modal marker and mediator in atherosclerotic vascular disease. Atherosclerosis. 2014; 236(2): 327 - 337.

9. Denhardt DT, Noda M, O’Regan AW, Pavlin D, Berman JS. Osteopontin as a means to cope with environmental insults:

regulation of inflammation, tissue remodelling and cell survival. J Clin Invest.

2001; 107(9): 1055 -1061.

10.Hu DD, Lin ECK, Kovach NL, Hoyer JR, Smith JW. A biochemical characterization of the binding of osteopontin to integrins alpha v beta 1 and alpha v beta 5. J Biol Chem 1995; 270(44): 26232 -26238.

11.Denda S, Reichardt LF, Müller U.

Identification of osteopontin as a novel ligand for the integrin alpha8 beta 1 and potential roles for this inte grin-ligand interaction in kidney morphogenesis. Mol Biol Cell. 1998; 9(6): 1425-1435.

12.Bayless KA, Meininger GA, Scholtz JM, Davis GE. Osteopontin is a ligand for the ɑ4ᵦ1 integrin. J Cell Sci. 1998; 111( Pt 9):

1165-1174.

13.Singh M, Dalal S, Singh K. Osteopontin: At the Cross-roads of Myocyte Survival and Myocardial Function. Life Sci. 2014; 118(1):

1 -6.

14.Dalal S, Zha Q, Daniels CR, Steagall RJ, Joyner WL, Gadeau AP, et al.

Osteopontin stimulates apoptosis in adult cardiac myocytes via the involvement of CD44 receptors, mitochondrial death pathway, and endoplasmic reticulum stress.

Am J Physiol Heart Circ Physiol. 2014;

306(8): 1182 -1191.

(11)

# 9 ) : ( " " / / / ;. # . # , ( 9 2. " # < ) =0 .

...

,# 2-#

" 2*

/

11

98

15.Huebener P, Abou-Khamis T, Zymek P, Bujak M, Ying X, Chatila K, et al. CD44 is critically involved in infarct healing by regulating the inflammatory and fibrotic response. J Immunol. 2008; 180(4): 2625- 2633.

16.Schunke KJ, Coyle L, Merrill GF, Denhardt DT. Acetaminophen attenuates doxorubicin- induced cardiac fibrosis via osteopontin and GATA4 regulation: reduction of oxidant levels. J Cell Physiol. 2013; 228(10): 2006 - 2014.

17.Renault MA, Robbesyn F, Réant P, Douin V, Daret D, Allières C, et al. Osteopontin expression in cardiomyocytes induces dilated cardiomyopathy. Circ Heart Fail 2010; 3(3):

431 -439.

18.Rubiś P, Wiśniowska-Śmiałek S, Dziewięcka E, Rudnicka-Sosin L, Kozanecki A, Podolec P. Prognostic value of ﬁbrosis-related markers in dilated cardiomyopathy: A link between osteopontin and cardiovascular events. Adv Med Sci. 2018; 63(1): 160-166.

19.Mohamadpour AH, Abdolrahmani L, Mirzaei H, Sahebkar AH, Moohebati M, Ghorbani M, et al .Serum Osteopontin Concentrations in Relation to Coronary Artery Disease. Arch. Med. Res. 2015;

46(2): 112-117. (In Persian).

20.Komatsubara I, Murakami T, Kusachi S, Nakamura K, Hirohata S, Hayashi J, et al.

Spatially and temporally different expression of osteonectin and osteopontin in the infarct zone of experimentally induced myocardial infarction in rats. Cardiovasc Pathol. 2003;

12(4): 186 -194.

21.Rosenberg M, Zugck C, Nelles M, Juenger C, Frank D, Remppis A, et al. Osteopontin, a

new prognostic biomarker in patients with chronic heart failure. Circ Heart Fail 2008;

1(1):43-49.

22.Satoh M, Nakamura M, Akatsu T, Shimoda Y, Segawa I, Hiramori K. Myocardial osteopontin expression is associated with collagen fibrillogenesis in human dilated cardiomyopathy. Eur J Heart Fail. 2005;

7(5): 755 -762.

23.Renault MA, Robbesyn F, Réant P, Douin V, Daret D, Allières C, et al. Osteopontin Expression in Cardiomyocytes Induces Dilated Cardiomyopathy. Circ Heart Fail. 2010; 3(3): 431 -439.

24.Fitzpatrick LA, Severson A, Edwards WD, Ingram RT. Diffuse calciﬁ cation in human coronary arteries. Association of osteopontin with atherosclerosis. J Clin Invest 1994; 94(4): 1597 -1604.

25.Kwan G and Balady GJ. Cardiac rehabilitation 2012: advancing the field through emerging science. Circulation 2012;

125(7): 369 -373.

26.Conraads VM, Beckers P, Vaes J, Martin M, Van Hoof V, De Maeyer C, et al. Combined endurance/resistance training reduces NT- proBNP levels in patients with chronic heart failure. Europ Heart J. 2004; 25(20): 1797- 1805.

27.Shiroma EJ and Lee IM. Physical activity and cardiovascular health: lessons learned from epidemiological studies across age, gender, and race/ethnicity. Circulation. 2010;

122(7):743 -752

28.Michael Sponder, Monika Fritzer‑Szekeres, Rodrig Marculescu, Brigitte Litschauer, Jeanette Strametz‑Juranek. Physical inactivity increases endostatin and osteopontin in patients with coronary artery

(12)

# 9 ) : ( " " / / / ;. # . # , ( 9 2. " # < ) =0 .

...

,# 2-#

" 2*

disease. Heart Vessels. 2016; 31(10): 1603- 1608.

29.Guide for the care and use of laboratory animals. 8thEdition. Washington DC: The National Academies Press. 2011.

30.Chilibeck P.D, Bell G.J, Farrar R.P, Martin T.P, Higher mitochondrial fatty acid oxidation following interval versus continuous endurance exercise training. Can.

J. Physiol. Pharmacol. 1998; 76(9): 891 -894.

31.Lau YS, Patki G, Das-Panja K, Le WD, Ahmad SO. Neuroprotective effects and mechanisms of exercise in a chronic mouse model of Parkinson's disease with moderate neurodegeneration. Eur. J. Neurosci. 2011;

33(7): 1264-1274.

32.David A. Morrow. Myocardial Infarction - A Companion to Braunwald’s Heart Disease.

20thEdition. Philadelphia: Elsevier. 2017.

33.Li M, Rao M, Chen K, Zhou J, Song J.

Selection of reference genes for gene expression studies in heart failure for left and right ventricles. Gene. 2017; 620: 30-35.

34.Pedersen BK and Saltin B. Evidence for prescribing exercise as therapy in chronic disease. Scand J Med Sci Sports. 2006; 16 (1): 3-63.

35.Vavouranakis I, Lambrogiannakis E, Markakis G, Dermitzakis A, Haroniti Z, Ninidaki C, et al. Effect of home-based intervention on hospital readmission and quality of life in middle-aged patients with severe congestive heart failure: a 12-month Follow up study. Eur J Cardiovasc Nurs.

2003; 2(2): 105-111.

36.Kurose S, Iwasaka J, Tsutsumi H, Yamanaka Y, Shinno H, Fukushima Y, et al. Effect of exercise-based cardiac rehabilitation on non- culprit mild coronary plaques in the culprit

coronary artery of patients with acute coronary syndrome. Heart Vessels. Heart Vessels. 2016; 31(6): 846-854.

37.Bjerre M, Pedersen SH, Mogelvang R, Lindberg S, Jensen JS, Galatius S, et al. High osteopontin levels predict long-term outcome after STEMI and primary percutaneous coronary intervention. Eur J Prev Cardiol.

2013; 20(6): 922 -929.

38.Okamoto H. Osteopontin and the cardiovascular system. Mol Cell Biochem.

2007; 300(1-2): 1 -7.

39.Mohamed IA, Mraiche F. Targeting osteopontin, the silent partner of Na+/H+

exchanger isoform 1 in cardiac remodeling. J Cell Physiol. 2015; 230(9): 2006-2018.

40.Mohamed IA, Gadeau AP, Fliegel L, Lopaschuk G, Mlih M, Abdulrahman N, et al. Na+/H+ Exchanger Isoform 1-Induced Osteopontin Expression Facilitates Cardiomyocyte Hypertrophy. PLoS One. 2015; 10(4): e0123318.

41.Xie Z, Pimental DR, Lohan S, Vasertriger A, Pligavko C, Colucci WS, et al. Regulation of angiotensin II-stimulated osteopontin expression in cardiac microvascular endothelial cells: role of p42/44 mitogen- activated protein kinase and reactive oxygen species. J Cell Physiol 2001; 188(1): 132 - 138.

42.La Gerche A, Burns AT, Mooney DJ, Inder WJ, Taylor AJ, Bogaert J, et al. Exercise- induced right ventricular dysfunction and structural remodelling in endurance athletes.

Eur Heart J. 2012; 33(8): 998-1006.

(13)

# 9 ) : ( " " / / / ;. # . # , ( 9 2. " # < ) =0 .

...

,# 2-#

" 2*

/

13

98

Pre-treatment effects of continuous and intermittent endurance training on gene expression of myocardial Osteopontin in male Wistar rats

following the induction of myocardial infarction.

Mohammadi Moghaddam A¹, Tadibi V^*2, Behpoor N², Nazari A^{3, 4}

1.Ph. D Candidate of Exercise Physiology, faculty of Sport Sciences, Razi University, Kermanshah. Iran.

2.Associate Professor, Department of Exercise Physiology, Faculty of Sport Sciences, Razi University, Kermanshah, Iran, [email protected]

3.Razi Herbal Medicines Research Center, Department of Physiology, Lorestan University of Medical Sciences, Khorramabad, Iran.

4.Cardiovascular Research Center, Shahid Rahimi Hospital, Lorestan University of Medical Sciences, Khorramabad, Iran.

Received: 6 April 2019 Accepted: 1 Jun 2019

Abstract

Background: Physical activity and sport act as a non-drug treatment and prevention of non- contagious diseases. Accordingly, one of the most widely used tools is endurance training. The aim of this study was to survey the pre-treatment effects of continuous and intermittent endurance training on the gene expression of osteopontin in the heart tissue of male wistar rats following the induction of myocardial infarction.

Materials and Methods: In the present study, 32 rats were kept under standard conditions and divided into four groups (healthy control group, ischemic control group, continuous training group and intermittent training group). The healthy control group did not undergo myocardial infarction, while the ischemic control group underwent induced myocardial infarction after eight weeks. The training groups also did endurance training on treadmills for eight weeks and were subjected to induced myocardial infarction after 48 hours of rest. One week after confirmed occurrence of ischemia, the rats’ hearts were isolated and qRT-PCR was used to measure OPN gene expression.

Results: The results of this research showed that OPN gene expression in the heart tissue of male wistar rats increased significantly after the induction of myocardial infarction compared to the healthy control group (p<0.05). Also, the relative expression of this gene in the ischemia control group was significantly higher than both the two training groups (p<0.05). Comparing the two types of training, the relative level of OPN expression in the group that underwent continuous training was lower (p<0.05).

Conclusion: Cardiac infarction leads to an increase in cardiovascular risk factors and cardiac fibrosis. Endurance training, especially regular continuous training, can moderate the increase in these factors.

Keywords:Osteopontin, Myocardial Infarction, Pre-treatment, Endurance Training.

*Citation: Mohammadi Moghaddam A, Tadibi V, Behpoor N, Nazari A. Pre-treatment effects of continuous and intermittent endurance training on gene expressions of myocardial Osteopontin in male wistar rats following myocardial infarction induction. Yafte. 2019; 21(2):1-13.

Pre-treatment effects of continuous and intermittent endurance training on gene expression of myocardial Osteopontin in male Wistar rats following the induction of myocardial infarction

/

98

! "

#$% & ' ( ) *% + ,

! / #

$ # %&'(

! /

2 /

&( * 98

-& & / 80

'

/

98

0 9

/

98

';#

9

/

98

b 'X ; 8

/

98

I F"

References

/

98

/

98

#$% & **' ( ) *% + ,**